Home Merck Initiates Rolling Submission of U.S. Biologics License Application for MK-3475, an Investigational Anti-PD-1 Immunotherapy, in Patients with Advanced Melanoma
 

Keywords :   


Merck Initiates Rolling Submission of U.S. Biologics License Application for MK-3475, an Investigational Anti-PD-1 Immunotherapy, in Patients with Advanced Melanoma

2014-01-13 14:30:00| Merck.com - Research & Development News

Dateline City: WHITEHOUSE STATION, N.J. Expects to Complete Application in First Half of 2014 WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, said today it has started a rolling submission to the U.S. Food and Drug Administration (FDA) of a Biologics License Application for MK-3475, the companys investigational anti-PD-1 immunotherapy, for patients with advanced melanoma who have been previously treated with ipilimumab. A rolling submission allows completed portions of the application to be submitted and reviewed by the FDA on an ongoing basis. Language: English Contact: MerckMedia:Ian McConnell, 908-423-3046Claire Mulhearn, 908-423-7425orInvestors:Carol Ferguson, 908-500-1101Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: with advanced application license

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
26.06VW to invest up to $5bn in Tesla rival Rivian
26.06Strategic use of soybean meal to maximize hog carcass weight during summer
26.06Eastern North Pacific Tropical Weather Outlook
26.06Atlantic Tropical Weather Outlook
26.06Aer Lingus pilots begin industrial action over pay dispute
25.06Water requirements in the summer
25.06New model Is transforming the study of liver abscesses in cattle
25.06Royal Mail buyer to make offer for all staff shares
More »